United States Patent 7,919,116: Scope, Claim Strength, and US Landscape

US Patent 7,919,116 has enforceable scope centered on a once-daily, fed-condition oral solid sustained release (SR) tablet of metformin hydrochloride with specific in vitro dissolution windows and an express exclusion: the tablet “does not employ an expanding polymer.” Claim 1 additionally ties the dissolution performance to a therapeutic exposure window (12 to 24 hours).

Because the patent is framed as a method of treating a human diabetic patient, enforceability is anchored to direct administration to patients using the claimed dosage regimen and product performance. The dissolution profile requirements in Claims 1 and 2 create clear, testable boundaries that can narrow infringement and support design-around strategies.

What do the claims cover at a product and method level?

Independent claim 1: core treatment method + product performance boundaries

Claim 1 requires all of the following, as a single integrated limitation set:

Patient and indication
- “A human diabetic patient.”
Dosage form
- “An oral solid sustained release tablet of metformin hydrochloride.”
Dosing regimen
- “Administering the sustained release tablet … once a day under fed conditions.”
Composition
- Sustained release tablet comprises:
  1. “metformin hydrochloride,” and
  2. “a sustained release material.”
- “The tablet does not employ an expanding polymer.”
Pharmacokinetic timing
- “Provides therapeutic plasma levels … over a 12 to 24 hour period after administration.”
In vitro dissolution profile (USP Type 2, 75 rpm, 900 mL pH 7.5 phosphate buffer, 37°C)
- 2 hours: 0-25%
- 4 hours: 10-45%
- 8 hours: 30-90%
- 12 hours: not less than 50%
- 16 hours: not less than 60%
- 20 hours: not less than 70%

This claim functions like a performance-parameter fence: a product can be outside infringement if it fails any dissolution threshold at the specified sampling times under the exact USP Type 2 conditions.

Dependent claim 2: narrower dissolution corridor

Claim 2 further specifies a tighter dissolution range:

2 hours: 0-15%
4 hours: 20-40%
8 hours: 45-90%
12 hours: not less than 60%
16 hours: not less than 70%
20 hours: not less than 80%

Compared with Claim 1, Claim 2 is more stringent at early timepoints (lower at 2 hours, narrower 4 hours) and more demanding at later timepoints (higher required release at 12/16/20 hours).

Dependent claims 3 and 4: fed-meal specificity

Claim 3: tablet is administered “with or after a meal.”
Claim 4: tablet is administered “with or after evening meal.”

These are treatment-dosing refinements that can drive infringement toward labels and real-world use patterns.

Dependent claim 5: osmotic tablet architecture

Claim 5: tablet “is an osmotic tablet with a homogeneous osmotic core.”

This introduces a structural limitation. Even if dissolution matches and there is no expanding polymer, an accused product that is not an osmotic tablet with a homogeneous osmotic core may avoid Claim 5.

What are the key infringement triggers and the main design-around levers?

Trigger 1: “fed conditions” and meal administration

The claim explicitly requires dosing “once a day under fed conditions.” That pushes infringement risk toward:

product labels that instruct administration with/after meals, and
patient instruction and practice consistent with fed dosing.

Design-around lever:

avoid “with or after a meal” instruction and instead structure product use around fasting dosing (where feasible and compliant).

Trigger 2: “does not employ an expanding polymer”

The claims exclude “expanding polymer.” If an accused formulation uses an expanding polymer, it is outside the express limitation of Claim 1. If it uses a non-expanding sustained release mechanism, it is within the compositional genus, subject to dissolution and dosing requirements.

Design-around levers:

incorporate an expanding polymer (if product feasibility and regulatory strategy allow), or
ensure formulation materials are outside what is construed as “expanding polymer.”

Trigger 3: dissolution performance at exact timepoints

The USP Type 2, pH 7.5 buffer, 75 rpm, 900 mL, 37°C conditions plus the release percentages create a measurable identity.

Design-around levers:

shift the release-time profile so it misses one or more windows. Examples at the edges:
- Too low at 12/16/20 hours (falls short of “not less than” thresholds).
- Too high early (exceeding 25% at 2 hours in Claim 1 or 15% in Claim 2; or exceeding the allowed band at 4 hours).

Trigger 4: osmotic “homogeneous osmotic core” (Claim 5 only)

Claim 5 adds an architecture constraint. If an accused tablet uses a different delivery architecture (non-osmotic, or osmotic but not homogeneous osmotic core), Claim 5 may be avoided even if Claim 1 is otherwise met.

Design-around lever:

use a non-osmotic SR architecture, or use osmotic design that does not match “homogeneous osmotic core” characterization.

How strong is the claim set as a patent barrier?

High clarity in performance-defined limits

Claims 1 and 2 are strong because they are anchored in:

specified dissolution apparatus and conditions, and
numeric release windows.

That structure supports:

litigation-ready infringement testing, and
defenses based on test deviations or failure to meet thresholds.

Risk concentration around once-daily fed SR metformin tablets

The claim is not broad across all metformin SR forms. It is specifically:

sustained release tablet of metformin hydrochloride,
once daily,
fed conditions,
no expanding polymer,
dissolution profile matching at 2/4/8/12/16/20 hours.

Potential vulnerability: narrowness vs breadth

The performance windows and “fed conditions” narrow the target universe. A product that:

is dosed fasted,
uses a different metformin salt form (not metformin hydrochloride),
employs expanding polymer,
or misses dissolution thresholds, can avoid the claim.

What is the practical claim chart structure for an accused product?

A workable infringement mapping framework for US Patent 7,919,116 looks like this:

Claim element	What must be shown	Typical evidence
Human diabetic patient treatment	A dosing method used in humans for diabetes	Labeling, prescribing, clinical/real-world use
Oral solid sustained release tablet of metformin hydrochloride	Product identity	NDA/ANDA documents, formulation descriptions
Once-daily under fed conditions	Administration schedule + fed dosing	Label instructions, patient instructions
Tablet comprises metformin HCl + sustained release material	Composition presence	Formulation listing, compositional specs
No expanding polymer	Absence of expanding polymer	Formulation components, excipient list, supplier docs
12-24 hour therapeutic plasma levels	Exposure duration	PK data
USP 2 dissolution meets windows	Match to numeric dissolution releases at timepoints	Dissolution testing under identical methods
Claim 2 enhanced windows	Match to tighter numeric corridor	Same as above
Claim 5 osmotic homogeneous core	Tablet architecture	Engineering description, sectional analysis

Where does this patent sit within the US metformin SR landscape?

Competitive technology areas likely adjacent to this claim

Even without other patent text provided here, the claim itself signals the technology boundaries that matter in the market:

sustained release metformin HCl tablets,
once-daily dosing,
dissolution-controlled release profiles,
osmotic delivery (at least for Claim 5),
non-expanding polymer compositions.

In the US, the metformin SR market has historically included both:

matrix-based and coated SR systems, and
osmotic delivery designs.

This patent is strongest against products that aim to replicate the specific dissolution timing and fed once-daily exposure pattern while avoiding expanding polymers.

Key “landscape” implication

A common infringement strategy for brand enforcement against SR metformin would be:

match the label dosing instruction to fed once-daily administration,
show the dissolution test profile meets Claim 1 (and ideally Claim 2),
then use the “does not employ an expanding polymer” limitation to exclude formulations that use expanding polymers.

Conversely, generic developers often focus on:

formulation and release profile shifts outside the dissolution windows,
modifying the dosing recommendation (if defensible),
or choosing a different SR mechanism.

What would be the most relevant claim boundaries for litigation?

Most decisive limitations (ranked by falsifiability)

Dissolution windows (Claims 1 and 2)
Numeric, testable, timepoint-based.
Fed-condition once-daily administration (Claims 1, 3, 4)
Label-based and practice-based.
No expanding polymer (Claim 1)
Component-based; requires formulation evidence.
Osmotic homogeneous core (Claim 5)
Product architecture-based.

Secondary but meaningful limitations

“Therapeutic plasma levels over 12 to 24 hours”
Useful if accused product’s dissolution matches but PK does not.

How does dependent claim 2 affect infringement strategy?

Claim 2 is a narrower performance window. In litigation, it can operate in two ways:

If an accused product meets Claim 2, it necessarily meets Claim 1 only if the Claim 1 windows are also satisfied. But Claim 2 does not automatically guarantee Claim 1 unless the ranges overlap as required.
If an accused product misses Claim 2 but still meets Claim 1, Claim 1 can still be asserted. This increases the importance of Claim 1 being broad enough.

In practice:

Claim 2 provides an additional “hook” if the accused dissolution profile lands in the tighter band.
Defense testing that targets one timepoint is less effective if multiple windows are asserted.

What are the most likely infringement and invalidity pressure points?

Infringement pressure points

Dissolution: close adherence to the exact USP Type 2 method and sampling times.
Fed dosing: reconciliation between label language and real-world administration method.
Expanding polymer: ensuring evidentiary support for the absence of expanding polymer (or showing an alternative formulation uses expanding polymer).

Invalidity pressure points (claim-specific)

This is claim-structure dependent:

Dissolution parameter claims can face challenges if the limits are treated as optimization of known SR performance characteristics.
Mechanism limitation “does not employ an expanding polymer” can draw disputes over:
- what constitutes an “expanding polymer,” and
- whether alternative polymers in accused formulations meet that definition.

Key Takeaways

US Patent 7,919,116 is a performance-parameter driven barrier built on a once-daily fed dosing method for metformin hydrochloride SR tablets, with an explicit exclusion of “expanding polymer.”
The claim’s enforceability hinges on meeting numeric USP Type 2 dissolution release windows at 2, 4, 8, 12, 16, and 20 hours under specified pH and hydrodynamics, plus patient dosing under fed conditions.
Dependent Claim 2 narrows the dissolution corridor and can strengthen enforcement where dissolution matches a tighter profile.
Dependent Claim 5 narrows further to osmotic tablets with a homogeneous osmotic core, creating a potential carve-out for non-osmotic SR products.

FAQs

What is the most critical claim element in 7,919,116?
The USP Type 2 dissolution profile windows in Claim 1 and Claim 2, tested at pH 7.5, 75 rpm, 900 mL, 37°C.
Does the patent cover fasted administration?
No. Claim 1 requires once-daily dosing “under fed conditions,” and Claims 3-4 specify meal and evening-meal administration.
How does the patent handle formulation mechanism like expanding polymers?
Claim 1 expressly states the tablet “does not employ an expanding polymer,” which creates a composition-based exclusion.
Does Claim 5 broaden the patent’s scope?
No. Claim 5 narrows to osmotic tablets with a homogeneous osmotic core, so it applies only if that architecture is present.
What testing standard does infringement rely on?
USP Type 2 apparatus at 75 rpm in 900 mL of pH 7.5 phosphate buffer at 37°C, with dissolution sampling at 2, 4, 8, 12, 16, and 20 hours.

References

[1] U.S. Patent 7,919,116. (Claims 1-5 as provided in prompt text).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	3101999	⤷ Start Trial
Australia	739226	⤷ Start Trial
Canada	2324493	⤷ Start Trial
China	1158999	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,919,116

Summary for Patent: 7,919,116